Proposal for size justification of expanded cohort at phase-2-recommended dose
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10637-009-9385-7.pdf
Reference6 articles.
1. Ratain MJ, Mick R, Schilsky RL, et al (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637–1643
2. Both CM, Calvert AH, Giaccone G, et al (2008) Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 44:19–24
3. Hunsberger S, Rubinstein LV, Dansey J, Korn EL (2005) Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med 24:2171–2181
4. Azad NS, Posadas EM, Kwitkowski VE, et al (2008) Combination targeted therapy with sorafenib and bavacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–3714
5. Penel N, Isambert N, Leblond P, et al (2009) « classical 3+3 design » versus « accelerated titration design: analysis of 270 phase 1 trials investigating anti-cancer agents. Invest New Drug; Under Press
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs;Clinical Cancer Research;2017-04-04
2. Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I;Bulletin du Cancer;2015-01
3. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours;British Journal of Cancer;2013-10-22
4. Role of the investigator in phase 1 trials of anticancer drugs;The Lancet Oncology;2012-12
5. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs;Investigational New Drugs;2010-07-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3